Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have stage IVB or recurrent cervical cancer.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma|
|Study Start Date:||April 2000|
|Study Completion Date:||May 2003|
- Evaluate the efficacy of arsenic trioxide in patients with stage IVB or recurrent cervical carcinoma.
- Determine the safety of this treatment in these patients.
OUTLINE: Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study over 10-19 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005999
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Carol Aghajanian, MD||Memorial Sloan-Kettering Cancer Center|